Extracorporeal Life Support in Infarct-Related Cardiogenic Shock
NEJM, 2023 · Multicenter randomized open-label trial across 44 centers in Germany and Slovenia (n=420)
Clinical question
Does routine early VA-ECMO reduce 30-day mortality in acute myocardial infarction complicated by cardiogenic shock undergoing early revascularization?
What the trial found
Routine early VA-ECMO did not reduce 30-day mortality in acute MI cardiogenic shock and significantly increased major bleeding and vascular complications.
Current guideline position
Routine early VA-ECMO is not supported for unselected AMI-related cardiogenic shock; use remains individualized for refractory shock, arrest, or bridge indications.
Clinical interpretation
Argues strongly against routine early VA-ECMO for all infarct-related cardiogenic shock. VA-ECMO remains a selective rescue/bridge strategy for refractory shock or arrest when the expected benefit outweighs bleeding and vascular risk; the trial does not define a single SCAI stage at which ECMO is mandatory or prohibited.
Specialist-level VV/VA ECMO bedside management: selection, cannulation, gas exchange, hemodynamics, anticoagulation, circuit troubleshooting, organ support, ultrasound, ECPR, weaning and decannulation.
Primary pump failure, SCAI staging (A–E), PAC hemodynamics (CPO, PAPi), inotrope selection, emergent revascularization, and mechanical circulatory support.